Opinion
Video
Drs Saeed and Shroff discuss the next patient profile, focusing on HCC treatment strategies following disease progression after first-line therapy.
Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously Treated PDAC
Innovative Research Continues to Propel Individualized GIST Treatments
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC